DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.
This study, called the DUET-study, is for men with prostate cancer that has spread to their bones, even in a limited way, and is still sensitive to hormone therapy after their first treatment, such as surgery. We are testing a new approach that alternates two types of radiation treatment: Lutetium-177 PSMA and Radium-223. The main goal is to see if this combined treatment approach is safe and practical to give to patients. We'll also be checking how well patients tolerate the treatment, how it affects their quality of life, and whether it helps control their cancer by looking at PSA levels and scans. This is an early-stage study, so we're learning a lot about this potential new treatment.
At a glance
What is this study about?
Imagine you or someone you know has been treated for prostate cancer, perhaps with surgery, but now the cancer has spread a little to the bones. This study is for men in that situation. It's looking at a new way to treat this type of cancer by combining two sorts of targeted radiation treatment.
The two treatments, Lutetium-177 PSMA and Radium-223, each work in slightly different ways to target and kill cancer cells. The idea is to give these treatments one after the other, in an alternating pattern. The research team wants to find out if giving these treatments in this sequence is safe for patients and if it's practical to deliver. Practicality means whether it can be given without too many delays due to side effects, or if patients feel too unwell to continue.
Beyond safety and practicality, the study will also look at how patients feel during and after treatment, including their overall quality of life and specific side effects like dry mouth. They'll also monitor the cancer's response by checking blood tests (PSA levels) and scans to see if the treatment is helping to keep the cancer under control. By understanding these things, doctors can decide if this new way of treating prostate cancer could be a good option for future patients.
Key takeaways
- This study is testing a new, combined radiation treatment for prostate cancer spread to bones.
- It aims to see if the treatment is safe and practical to give to patients.
- The study is for men who have already had initial prostate cancer treatment and whose cancer responds to hormone therapy.
- It will monitor side effects, quality of life, and how well the cancer responds.
- Patients will receive two types of treatment given alternately, along with regular check-ups and scans.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
This study is specifically looking for men aged 18 or older who have prostate cancer.
To be considered for the study, your prostate cancer must have spread to your bones, but only in a limited way (known as 'oligometastatic' in medical terms). Importantly, your cancer must also still respond to hormone therapy, and you should have already had your initial cancer treatment, such as a prostate removal operation (radical prostatectomy).
Paticipants will undergo careful checks to ensure they meet all the study’s health requirements to ensure their safety. If you are a male fitting this description, a doctor or nurse will be able to tell you if you might be suitable for this particular study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Am I male?
- Am I at least 18 years old?
- Do I have prostate cancer that has spread to my bones, but only a limited number of spots?
- Has my prostate cancer already been treated (e.g., with surgery)?
- Does my prostate cancer still respond to hormone therapy?
- Am I willing to have regular appointments for treatment, tests, and scans?
What does participation involve?
If you join this study, you'll receive two types of radiation treatment, Lutetium-177 PSMA and Radium-223, given one after the other over a period. This means you will have appointments for injections or infusions of these treatments. You'll have regular hospital visits for check-ups, blood tests, and scans (like PSMA PET/CT, bone scan, and CT scans of your belly and chest) to monitor your health and how the treatment is working. You'll also be asked to complete questionnaires about your quality of life and any side effects, particularly dry mouth, at the start and repeatedly throughout the study. The doctors will monitor for side effects, especially those affecting your blood count or causing dry mouth. The total duration of the treatment and follow-up period will involve appointments for a number of months after your last treatment.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What kind of cancer is this study for?
It's for prostate cancer that has spread to a few places in the bones and still responds to hormone treatment, especially after initial treatment like surgery.
What are Lutetium-177 PSMA and Radium-223?
These are both types of targeted radiation treatment given to help kill cancer cells.
What does 'Feasibility Study' mean?
It means the main aim is to see if this new combined treatment is safe and practical enough to be given to patients without too many problems or delays.
What kind of tests will I have?
You'll have blood tests, scans like PSMA PET/CT, bone scans, and CT scans, and you'll fill out questionnaires about how you're feeling.
Can I stop being in the study if I want to?
Yes, you can choose to stop participating at any time without it affecting your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.